Skinvisible Inc. (SKVI)
OTCQB OTCQB Primary Summary
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / October 3, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical pharmaceutical research and development company, today announced the publication of an article highlighting the Company's innovative development of transdermal delivery of glucose-controlling agents using its proprietary delivery system Invisicare®. The article, titled "Advancements in Transdermal Delivery Systems: A Focus on Invisicare Technology for Obesity Treatment," was published in Drug Development & Delivery in its October issue.
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical pharmaceutical research and development company, today announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose- controlling drugs) including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare® technology; a polymer delivery vehicle that does not require a patch or needles. The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of obesity drugs and other glucose-controlling agents.
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an innovative topical / transdermal pharmaceutical research and development company, today announced the filing of a second patent application for its groundbreaking Invisicare® technology and its transdermal delivery of obesity and glucose-controlling agents. This new application significantly broadens the scope of the Company's initial patent application titled "Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery," previously announced in May, encompassing a wider range of active ingredients and additional conditions beyond obesity that can benefit from glucose-controlling agents such as diabetes.
Skinvisible Inc. (SKVI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Skinvisible Inc. ever had a stock split?
Skinvisible Inc. Profile
| Household Products Industry | Consumer Staples Sector | Terry H. Howlett CEO | OTCQB Exchange | 830703203 CUSIP |
| US Country | 2 Employees | - Last Dividend | 4 Jan 2019 Last Split | 7 Jan 1999 IPO Date |
Overview
Skinvisible, Inc., together with its subsidiaries, is a company dedicated to innovating in the field of polymer-based delivery system technologies and formulations specifically designed for application on the skin, through transdermal routes, or on mucosal membranes. Originating as Microbial Solutions, Inc. before rebranding in February 1999, Skinvisible has been pushing the boundaries of topical pharmaceutical, over-the-counter, personal skincare, and cosmetic products since its incorporation in 1998. Operating out of Las Vegas, Nevada, the company has built its reputation on delivering unique solutions that enhance the performance and consumer appeal of skin health and beauty products, extending the life cycle of existing pharmaceutical compounds through its patented Invisicare technology. With a focus on addressing a wide array of market needs from sun protection to pain management, Skinvisible’s approach combines technical innovation with strategic partnerships, offering its expertise and proprietary technologies to pharmaceutical entities and cosmetic brands seeking to set their products apart in the marketplace.
Products and Services
- Pharmaceutical Formulations:
- Over-the-Counter and Personal Skincare:
- Cosmetics:
- Sun Protection Products:
- Licensing and Development Services:
Skinvisible provides advanced delivery system technologies for pharmaceuticals aimed at enhancing the efficacy and application of topical and transdermal products. This includes a variety of therapeutic areas such as pain management and women's health, indicating the company's commitment to addressing a broad spectrum of healthcare needs with innovative skin delivery solutions.
The company extends its technological advancements to the over-the-counter and personal skincare sectors, offering formulations that improve the performance of skincare products. This includes enhancing the durability, effectiveness, and sensory experience of cosmetic and skincare applications, meeting the consumer's demand for high-quality personal care products.
Within the cosmetics arena, Skinvisible leverages its polymer-based delivery systems to offer innovative solutions that enhance the application and longevity of cosmetic products, providing added value to the consumer and differentiating cosmetic brands in a competitive market.
A key area of focus for Skinvisible is the development of sun protection products, including sunscreens and sunless tanning solutions, utilizing its proprietary technologies to offer enhanced UVA/UVB protection, longer-lasting effects, and improved skin feel, catering to the growing consumer awareness and demand for effective and comfortable sun care products.
Skinvisible offers valuable services to pharmaceutical companies through licensing agreements and early development assistance for formulations. This allows pharmaceutical partners to reformulate and extend the patent life of their products with Skinvisible’s Invisicare technology, thus achieving new product benefits and line extensions, ensuring commercial viability, and maintaining a competitive edge in the market.
